|
시장보고서
상품코드
2032385
심장 바이오마커 시장 보고서 : 유형, 검사 장소, 용도, 지역별(2026-2034년)Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2026-2034 |
||||||
세계의 심장 바이오마커 시장 규모는 2025년에 123억 달러에 이르렀습니다. 향후 IMARC Group은 2026-2034년 CAGR은 7.15%를 나타내, 2034년까지 233억 달러에 이를 것으로 예측했습니다.
심장 바이오마커는 심장에 부하가 걸리거나 심근이 손상되었을 때 혈류로 방출됩니다. 이러한 바이오마커에는 심장 트로포닌, 크레아틴 키나아제(CK), 허혈성 변형 알부민(IMA), 미오글로빈 등 다양한 유형의 효소, 호르몬, 단백질이 포함됩니다. 이러한 바이오마커의 측정 및 검사는 심장 허혈 및 급성관상동맥증후군(ACS)과 같은 심장 질환을 진단하는 데 도움이 됩니다. 현재 이러한 질병의 위험을 판단하는 데 사용되는 선별 및 진단 시스템은 심전도(ECG)와 병력을 기반으로 합니다. 그러나 이러한 시스템은 불충분하며, 오진이나 치료 지연으로 이어질 수 있습니다. 심장 바이오마커 검사는 정확도가 높고 발병 초기에 질병을 확인할 수 있어 전 세계적으로 주목받고 있습니다. 또한, 이러한 바이오마커는 질병의 예후를 보다 정확하게 모니터링하고 환자에게 가장 효과적인 치료법을 제공하는 데 도움이 됩니다.
세계 심장 바이오마커 시장 성장 촉진요인 :
최근 몇 년 동안 급성관상동맥증후군(ACS) 환자 수가 증가하고 있으며, 이로 인해 전 세계적으로 심장 바이오마커 검사에 대한 수요가 증가하고 있습니다. 이와 더불어, 다양한 심혈관 질환(CVD)의 조기 진단의 중요성에 대한 환자 및 의료진의 인식이 높아짐에 따라 이러한 바이오마커에 대한 수요가 증가하고 있습니다. 또한, 심장 바이오마커 분야의 첨단 기술 개발을 위해 수많은 민간 및 공공 기관이 연구개발(R& : D) 활동에 투자하고 있습니다. 예를 들어, 고감도 심장 트로포닌 I 혈액 검사는 재발성 심근경색 위험이 높은 환자를 식별할 수 있는 것으로 입증되었습니다. 또한, 바이오마커 검사가 제공하는 높은 정확도와 빠른 결과, 그리고 저렴한 가격의 심장 현장 검사가 가능하다는 점도 시장 성장에 기여하는 요인 중 하나입니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 심장 바이오마커 시장
제6장 시장 분석 : 유형별
제7장 시장 분석 : 검사 시행 장소별
제8장 시장 분석 : 용도별
제9장 시장 분석 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KTH 26.05.15The global cardiac biomarkers market size reached USD 12.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 23.3 Billion by 2034, exhibiting a growth rate (CAGR) of 7.15% during 2026-2034.
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS) . At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.
GLOBAL CARDIAC BIOMARKERS MARKET DRIVERS:
Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.
KEY MARKET SEGMENTATION:
Breakup by Type:
- Troponins (T and I)
- Myocardial Muscle Creatine Kinase (CK-MB)
- Myoglobin
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Others
Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others. Breakup by Location of Testing:
- Laboratory Testing
- Point of Care Testing
Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.
Breakup by Application:
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others
Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.
Regional Insights:
- North America
- Asia Pacific
- Europe
- Middle East and Africa
- Latin America
Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.
COMPETITIVE LANDSCAPE:
The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cardiac Biomarkers Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Type
- 5.5 Market Breakup by Location of Testing
- 5.6 Market Breakup by Application
- 5.7 Market Breakup by Region
- 5.8 Market Forecast
6 Market Breakup by Type
- 6.1 Troponins (T and I)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Myocardial Muscle Creatine Kinase (CK-MB)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Myoglobin
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Ischemia Modified Albumin (IMA)
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Location of Testing
- 7.1 Laboratory Testing
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Point of Care Testing
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Application
- 8.1 Myocardial Infarction
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Congestive Heart Failure
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Acute Coronary Syndrome
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Atherosclerosis
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Europe
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Middle East and Africa
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Latin America
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
10 Global Cardiac Biomarkers Industry: SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Global Cardiac Biomarkers Industry: Value Chain Analysis
12 Global Cardiac Biomarkers Industry: Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Global Cardiac Biomarkers Industry: Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.2 Alere Inc.
- 14.3.3 Beckman Coulter
- 14.3.4 Becton, Dickinson And Co.
- 14.3.5 Biomerieux
- 14.3.6 Bio-Rad Laboratories
- 14.3.7 Randox Laboratories
- 14.3.8 Roche Diagnostics Corporation
- 14.3.9 Siemens Healthcare
- 14.3.10 Thermo Fisher Scientific
